

**Curriculum Vitae
Kathryn Ann Morton, M.D.**

I. PERSONAL DATA:

Date of Birth: November 8, 1951
Place of Birth: Kemmerer, Wyoming
Citizenship: United States of America

Office (correspondence): Dept. of Radiology and Imaging Sciences
University of Utah Hospital and Clinics
30 N. 1900 E. #1A71
Salt Lake City, UT 84132
Telephone 801-581-7553
Pager 801-339-4240
Cell phone 801-674-9381
Email: kathryn.morton@hsc.utah.edu

Academic address: Dept. of Radiology and Imaging Sciences
1A71, 50 N. Medical Drive
University of Utah School of Medicine
Salt Lake City, UT 84132

II. CURRENT TITLE/APPOINTMENTS:

Professor of Radiology with Tenure
Dept. of Radiology and Imaging Sciences
University of Utah School of Medicine
Salt Lake City, UT

III. EDUCATION:

Baccalaureate degree:
University of Utah, Salt Lake City, UT, B.S. (Biology) 1978

Advanced degree: Univ. of Utah, Salt Lake City, UT (M. D.) 1982

Post-doctoral clinical training:
Internship, Univ. of N.C. Chapel Hill, N.C., (Pediatrics) 1982-1983
Residency, Univ. of Utah, Salt Lake City, UT (Nuclear Medicine) 1983-84
Residency, Univ. of Utah, Salt Lake City, UT (Diagnostic Radiology), 1984-87

Research training:
Pre-doctoral research fellowship, metallobiochemistry, 1980-1981
Div. of Hematol./Oncol.,
University of Utah, Salt Lake City, UT

James P. Kushner, MD, preceptor

Pre-doctoral research fellowship, molecular biology, 1981-1982
Dept. of Cellular, Viral, & Molecular Biology
University of Utah, Salt Lake City, UT
Ellie Ehrenfeld, PhD., preceptor

IV. CERTIFICATION AND LICENSURE:

Medical Licensure (current):

North Carolina, #200100432 2001-current
Utah, #171062 1983-1/31/24
Idaho, #M16661 2022-6/30/23
DEA #BM2922727 1992-1/31/25
NPI #1891885406

Certification:

National Board of Medical Examiners, Diplomate, #263774
Part I 6/80
Part II 9/81
Part III 3/83

American Board of Radiology, Diplomate, #31242DS07107 6/11/87
Diagnostic Radiology with Special Competency in Nuclear Radiology

American Board of Nuclear Medicine, Diplomate, #05283, 9/12/87

V. PROFESSIONAL POSITIONS:

Professional Positions:

Staff Radiologist 7/22-present
Summit Physician Specialists (Intermountain Health Care)
Murray, UT

Faculty member, Tenured Full Professor 10/05-7/22
Department of Radiology and Imaging Sciences
University of Utah School of Medicine
Salt Lake City, UT

Section Chief, Nuclear Medicine 2016- 2021
University of Utah Department of Radiology and Imaging Sciences
Salt Lake City, UT

Director, Nuclear Medicine and Positron Emission Tomography 7/04-10/07
Department of Radiology
University of Utah School of Medicine
Salt Lake City, UT

Director, Translational PET Research 4/01-7/04
Vice-Chairman for Research
Director, Nuclear Medicine and Positron Emission
Wake Forest University School of Medicine
Winston-Salem, NC

Chief, Imaging Service (Radiology and Nuclear Medicine) VA Medical Center, Portland, OR	5/95-4/01
Chief, Nuclear Medicine Service VA Medical Center, Portland, OR	1/95-5/95
Chief of Nuclear Medicine VA Medical Center, Salt Lake City, UT	7/87 - 1/95
Academic Positions:	
Award of tenure (Clinical scholar track) University of Utah	7/1/2009
Professor of Radiology University of Univ. School of Medicine, Salt Lake City, UT	5/05-2022
Visiting Instructor University of Univ. School of Medicine, Salt Lake City, UT	7/04-5/05
Professor of Radiology Wake Forest Univ. School of Medicine, Winston-Salem, NC	4/01-7/04
Professor of Radiology Oregon Health Sciences University, Portland, OR	7/98-4/1/01
Associate Professor of Radiology Oregon Health Sciences University, Portland, OR	1/95-7/98
Associate Professor of Radiology (Academic Track) University of Utah, Salt Lake City, UT	7/92-1/95
Award of tenure (Academic track) University of Utah, Salt Lake City, UT	7/94
Assistant Professor of Radiology (Academic Track) University of Utah, Salt Lake City, UT	7/87 -6/92
Editorial Experience:	
Referee: Multiple imaging journals	1988-present
Reviewer of abstracts, Society of Nuclear Medicine Meeting	1991-present
Reviewer of abstracts, RSNA	2004-present
Consulting Editor, Journal of Nuclear Medicine Technology	1997-2001
Activity as Member of Research Study Sections for grant review:	
Federal:	
115 NIH study sections	1988-present
Chairman of 17 study sections	
Member of 11 Charter study sections	

DOE, Nuclear Medicine Education Award Study Section	2000
Ad hoc reviewer: VA research grants	1989-2001
Member of study section, Department of Energy Research Instrumentation Award	1989-90 cycle
National (non-Federal):	
Chairman, RSNA Grants Program Committee	2013-2014
Chairman, RSNA Diagnostic Radiology Study Section	2012-2013
Member, Study Section RSNA Research and Education Foundation	1996-2018
Member, Study Section RSNA Medical Student Research Program	2007-2010
Member, Study Section California Breast Cancer Research Program	March, 2003
Member, Society of Nuclear Medicine Student Fellowship Committee Education and Research Foundation	1990-2001
Local:	
Medical Student Research Committee University of Utah, Salt Lake City, UT	2005-2015
Oregon Health Sciences University Research Committee Portland, Oregon	1997-1999
Research and Development Committee VA Medical Center, Portland, OR	1996-1999
Research and Development Committee, VA VA Medical Center, Salt Lake City, UT	1990-1993
Chairman, Research and Development Committee VA Medical Center, Salt Lake City, UT	1992-1993
Administrative Experience and Service Positions	
Local:	
Chief, Nuclear Medicine Section University of Utah Department of Radiology and Imaging Sciences Salt Lake City, UT	2017-2021
Executive Committee University of Utah Department of Radiology and Imaging Sciences Salt Lake City, UT	2017-2021

Huntsman Cancer Program Leader Committee University of Utah Salt Lake City, UT	2004-2022
Huntsman Cancer Center Member and Investigator University of Utah Salt Lake City, UT	2004-2022
Radiation Safety Committee University of Utah School of Medicine Salt Lake City, UT	2006-2022
Academic Appeals Committee College of Humanities University of Utah Salt Lake City, UT	2015-2022
Site Radiation Safety Officer, Redwood Clinic University of Utah Hospital and Clinics Salt Lake City, UT	2008-2017
Academic Senate University of Utah School of Medicine Salt Lake City, UT	2008-2011
Radiation Safety Committee VA Medical Center Salt Lake City, UT	2006-2012
Medical Student Research Committee University of Utah School of Medicine Salt Lake City, UT	2004-2010
Director, Nuclear Medicine and PET University of Utah School of Medicine Salt Lake City, UT	2004-2005
Director, Nuclear Medicine and PET Director, Translational PET Research Director, Nuclear Medicine Training Program Wake Forest University Health Sciences Winston-Salem, NC	2001-2004
Member, Internal Advisory Board Comprehensive Cancer Center Wake Forest University Health Sciences Winston-Salem, NC 2001-present	2001-2004
Member, Executive Board Neuroscience Center of Excellence Wake Forest Univ. School of Medicine	2002-2004

Winston-Salem, NC

Co-Leader, Bioanatomic Research Group 2002-2004
Neuroscience Center of Excellence
Wake Forest Univ. School of Medicine
Winston-Salem, NC

Chief, Imaging Service (Radiology and Nuclear Medicine) 1995-2001
VA Medical Center, Portland, OR,

Chief, Nuclear Medicine Service 1/95-5/95
VA Medical Center, Portland, OR,

Chief of Service, Nuclear Medicine 1987-1995
VA Medical Center, Salt Lake City, UT

Medical Staff Council 1999-2001
VA Medical Center, Portland, OR,

Executive Oversight and Operations Group 1997-2001
VA Medical Center, Portland, OR

Strategic Planning Technology Development Team 1997-2001
VA Medical Center, Portland, OR

Equipment Committee 1995-2001
VA Medical Center, Portland, OR,

Education Committee 1995-2001
Oregon Health Sci. Univ.
Dept. of Diag. Radiology, Portland, OR

Selection Committee for Chairman 1999-2001
Department of Surgery
Oregon Health Sciences University, Portland, OR

Selection Committee for Chair 1997
Department of Emergency Medicine
Oregon Health Sciences University, Portland, OR

Selection Committee for Chairman 1997
Ophthalmology Department
Oregon Health Sciences University, Portland, OR,

Selection Committee for Chief of Staff 1997
VA Medical Center, Portland, OR,

Selection Committee 1997
Chief of Mental Health Division/Psychiatry Service
VA Medical Center, Portland, OR,

Radiation Safety Committee 1996

VA Medical Center, Portland, OR	
Selection Committee for Chairman Dermatology Department Oregon Health Sciences University, Portland, OR	1996
Dean's Committee University of Utah Medical School Salt Lake City, UT,	1987-1995
Professional Standards Board VA Medical Center, Salt Lake City, UT	1990-1995
Academic Senate, Senator from School of Medicine University of Utah, Salt Lake City, UT	1994-1995
Member, Academic Senate: Academic Freedom and Tenure Subcommittee, University of Utah , Salt Lake City, UT	1994-1995
Member, Academic Senate: Personnel and Elections Subcommittee University of Utah, Salt Lake City, UT,	1994-1995
Medical Student Research Committee University of Utah, Salt Lake City, UT	1988-1995
Clinical Executive Board VA Medical Center, Salt Lake City, UT	1987-1995
Chief of Staff Advisory Committee VA Medical Center, Salt Lake City, UT	1987-1995
Radiation Safety Committee VA Medical Center, Salt Lake City, UT	1987-1995
Medical Imaging Research Laboratory Advisory Board University of Utah, Salt Lake City, UT	1987-1988
Administrative Executive Board VA Medical Center, Salt Lake City, UT	1987-1990
Research and Development Committee VA Medical Center, Salt Lake City, UT	1990-1993
Research and Development Committee, Chairman VA Medical Center, Salt Lake City, UT	1992-1993
Equipment Committee VA Medical Center, Salt Lake City, UT	1989-93
Foreign Travel Committee	1988-1994

VA Medical Center, Salt Lake City, UT	
Member, Special Board of Investigation VA Medical Center, Salt Lake City, UT,	1990-1991
Regional:	
Delegate from Pacific NW Chapter Society of Nuclear Medicine	1998-2001
President, Oregon Radiological Society (ACR Chapter)	1998-1999
Teleradiology Task Force Department of Veterans Affairs VISN #20	1997-2000
Oregon Radiological Society Educational Program Co-Director	1996-2000
Oregon Health Plan Technology Evaluation Committee	1997-2000
Member, Regional High Technology Equipment Task Force Department of Veterans Administration, Western Region,	1991-1993
President, Rocky Mountain Chapter Society of Nuclear Medicine	1989-1991
Member, Western Regional Steering Committee Society of Nuclear Medicine	1989-91
Vice President, Rocky Mountain Chapter Society of Nuclear Medicine,	1987-1989
Member, District Oncology Advisory Committee VA Medical Center, Salt Lake City, UT	1988-89
International/National:	
Reviewer of abstracts for SNMMI and RSNA	Yearly
Member, RSNA Scientific Program Committee	2013-2020
Moderator of scientific sessions, RSNA annual meetings	2004-current
Moderator of scientific sessions, Society of Nuclear Medicine Annual Meeting	1991-current
Member, RSNA Publications Council	2017-current
Member and Chairman, External Advisory Board Center for Translational and Cancer Nanomedicine Memorial Sloan Kettering Cancer Center and Cornell University New York City, NY	2016-current

Member, RSNA R&E Evaluations Committee	2016 – 2020
NIH Advisory Council for Biomedical Imaging	2017
Member, search committee to select Editor-in-Chief for Radiology Radiological Society of North America	2016
Member, National Academies of Science and Medicine Committee, State of Molybdenum-99 Production and Utilization and Progress Toward Eliminating Use of Highly Enriched Uranium	2015 - 2016
Committee on Standards and Accreditation Commission on Nuclear Medicine American College of Radiology	1999-2007
Procedural Guidelines Author, Society of Nuclear Medicine	1995-2009
Member, ACRIN Breast Cancer Council	2003-2006
Member, Association of University Radiologists Board of Directors	2003-2004
American Roentgen Ray Society, Scientific Program Committee	2001-2003
Delegate from Pacific Northwest Chapter to National Society of Nuclear Medicine House of Delegates	1999-2002
Program Committee Member SNM Western Regional Meeting	October, 1999
Program Chairman Pacific Northwest Chapter Society of Nuclear Medicine for annual meeting	March, 1999
Member, International group For consensus report on ACE inhibitor renography	1994-1995
Nominating Committee, Society of Nuclear Medicine	1989-1991
Board of Trustees, Society of Nuclear Medicine	1989-1991
Chapter President's Committee, Society of Nuclear Medicine	1989-1991

X. **GRANT SUPPORT**

Federally funded grants

NIH RO1 NS 092458-05 Morton (communicating PI, MPI) 4/01/15-3/30/21
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy
 This project focuses on better understanding the role that sepsis plays in secondary inflammation in the brain and its short and long-term neurocognitive consequences. The project will also develop the best imaging strategy for identifying the pathological changes that occur in the brain following sepsis. Finally, it will address aggressive immune modulation as a method for preventing sepsis-induced brain damage.

Role: Communicating PI

NIH R21 CA167795-01 Morton, Hoffman (co-PI's) 9/1/12-8/31/15
Multi-tracer PET assessment of response to novel targeted chemotherapy
To develop an imaging strategy for best predicting response to novel targeted chemotherapies.
Role: Co-PI

NIH 7R01DK088375-03 Lee, Vivian (PI) 6/01/10-5/31/15
Accurate measurements of renal function in cirrhosis
To develop and validate MR-based methods for assessing glomerular filtration rate in patients with cirrhosis.
Role: Co-I

1 R01 HL108350-01A1 Zeng Larry (PI) 12/01/11-11/30/15
Segmented-Parallel-Beam Stationary Cardiac SPECT
The objective of this project is to develop a stationary cardiac SPECT (single photon emission computed tomography) system using a novel segmented parallel-hole collimator mounted on a large-area NaI(Tl) detector. This stationary SPECT system is inexpensive to build, motion-free, and able to acquire consistent
Role: Co-I

NIH R21 CA128228-01 Hoffman, John (PI) 5/01/07-4/30/11
FDG-PET/CT in the evaluation of persistent febrile neutropenia in cancer patients
To conduct a pilot clinical trial to establish the utility and cost-effectiveness of PET/CT using the widely available glucose analogue [¹⁸F]fluoro-2-deoxy-glucose (FDG) in identifying sites of infection in cancer patients with persistent febrile neutropenia without an obvious identifiable source.
Role: Co-I

NIH R01CA121003-01A1 Morton (PI) 9/01/06-7/31/10
FDG PET in cancer-associated venothromboembolic disease
To explore the mechanism of FDG accumulation in acute thrombosis, the utility of FDG PET in the diagnosis of venothromboembolic (VTE) disease, and in the diagnosis of cancer in patients with unprovoked VTE.
Role: PI

NIH R21EB005728-01-A1 Morton (PI) 4/01/06-3/31/09
Imaging phenotypes in copper metabolism disease in mice
To define the unique imaging phenotypes, using Cu-64 PET, which characterize rodent models of human disorders of copper metabolism.
Role: PI

NIH/NCI R01CA107353 Kadrmas, Dan (PI) 1/1/05 – 12/31/08
Statistical PET Image Reconstruction
This project will develop advanced image reconstruction methods for PET, PET/CT, and CT-based partial-volume compensation methods for PET/CT imaging.
Role: Co-I

NIH/NIDDS R21DK067247 Clark, Paige (PI) 4/1/04-3/31/06
PET imaging of the pancreas in murine models of diabetes.

The major goal is to identify early changes in cholinergic innervations of the pancreas using molecular imaging techniques in a murine model of diabetes.

Role: Co-I

NIH/NIDA 5P50DA006634 Childers, Steven (PI) 2003-2008

Center for the Neurobiology of Addiction Treatment (CNAT).

The goal of the Center for the Neurobiology of Addiction Treatment is to study the neurobiological mechanisms of these drugs in models including cell culture, rodents and non-human primates, so that better strategies of drug treatment can be developed.

Role (PI for Imaging Core)

NIH/NCI RO1CA77574 Morton (PI) 02/12/98 – 07/31/06

Tumor imaging with Ga-67 by photodegraded nifedipine

The major goal of this project is to determine the biological mechanisms by which nitrosipine enhances tumor uptake of Ga-67.

Role: PI.

VA Merit Review Grant Morton (PI) 1993-1998

Tumor Imaging with Radiometals that Bind to Metallothionein

Role: PI

VA RAG Grant Morton (PI) 1988-1993

Tumor Imaging with Radiometals that Bind to Metallothionein

Role: PI

National Non-Federally Funded Research Grants:

RSNA Seed Grant Morton (PI) 1987-1988

Tumor Imaging with Radiometals that Bind to Metallothionein

Role: PI

Local Grants

Benning Grant Morton (PI) 1/1/05 -12/-30/05

Characterizing the Sigma-2 receptor

This project is aimed at purifying and characterizing the Sigma-2 receptor, a PET target surrogate for proliferation of breast cancer.

Role: PI

IX. MEMBERSHIP IN PROFESSIONAL SOCIETIES:

Society of Nuclear Medicine and Molecular Imaging

Radiological Society of North America

American College of Nuclear Physicians

XI. HONORS

Teacher of the Year (by Radiology Residents, University of Utah) 2022

American Journal of Radiology and Nuclear Medicine, Best paper 2018

American Journal of Radiology and Nuclear Medicine, Most cited paper 2018

Council of Distinguished Investigators of the Academy for Radiology and Biomedical Imaging Research	2018
Nighthawk of the Year (by Radiology Residents, University of Utah)	2013
Teacher of the Year (by Radiology Residents, University of UT)	2007
Member, ACRIN Breast Committee	2004-2006
Member, AUR Board of Directors	2003-2004
Invited participant, ACRIN/ACR Special Imaging Workshop –	2003
Teacher of the Year (by Radiology Residents, Oregon Health Sci Univ)	1998
RSNA, Research and Development Award (RSNA Seed Grant),	1987-1988
Invited Participant, Metallothionein in Carcinogenesis (NCI workshop)	1991
Outstanding medical student research award, Western Section, AFCR	1982

XII. PATENTS AND INVENTIONS:

Enhancement of cellular gallium uptake.

Inventors: Morton; Kathryn A. (Portland, OR); Roulet; Jean-Baptiste (Portland, OR)

Assignees: Oregon Health and Science University (Portland, OR), Department of Veterans Affairs

Appl. No.: 647954

Filed: October 6, 2000

PCT Filed: April 8, 1999

PCT NO: PCT/US99/07879

PCT PUB.NO.: WO99/51277

XIII. BIBLIOGRAPHY:

A. Papers:

1. Morton KA, Kushner JP, Burnham BF, and Horton WJ. Biosynthesis of porphyrins and heme from 4,5 -dioxovalerate (DOVA) by intact hepatocytes. Proc Natl Acad of Sci U.S.A. 78: 5335-5339. 1981. PMID: 6946473;
2. Morton KA, Kushner JP, Straka JG, and Burnham BF. Biosynthesis of 5-aminolevulinic acid and heme from 4,5-dioxovalerate in the rat. J Clin Invest 71 (6): 1744-1749, 1983. PMID: 6863542; PubMed Central PMCID: PMC370379.
3. Richards OC, Morton K, Martin SC, and Ehrenfeld E. Two forms of poliovirus VPg result from amino acid modification of a single viral protein. Virol 136: 453-456. 1984. PMID: 6087555.
4. Alazraki N, Dries DJ, Lawrence PF, Morton K, Datz FL and Taylor A. Assessment of skin ulcer healing capability by Tc99m phosphate angiogram and blood pool images. J Nucl Med 26: 586-591. 1985.

5. Morton KA, Alazraki NP, Taylor AT, and Datz FL. SPECT thallium scintigraphy for the detection of left-ventricular aneurysm. *J Nucl Med* 28: 168-172, 1987. PMID: 3492595.
6. Morton KA, Alazraki NP, Datz FL, Winge D, and Lynch RE. Uptake of cadmium-109, a metallothionein-binding radiometal, by tumors in mice as a function of the transformed phenotype. *Invest Radiol* 23: 200-204, 1988. PMID: 3372178.
7. Scuderi AJ, Datz FL, Christian PE, Handy JE, Fortner AA and Morton KA. Dipyridamole thallium-201 myocardial scintigraphy. *J Nucl Med Technol* 16: 119-123, 1989.
8. Goates JJ, Morton KA, Wooten WW, Greenberg HE, Datz FL, Handy JE, Scuderi AJ, Haakenstad, AO, and Lynch RE. Comparisons of methods for calculating glomerular filtration rate: Technetium-99m-DTPA scintigraphic analysis, protein-free and whole-plasma clearance of technetium-99m-DTPA and iodine-125-iothalamate clearance. *J Nucl Med* 31: 424-429, 1990. PMID: 2182797.
9. Gabor FV, Datz FL, Christian PE, Gullberg, GT, Morton, KA. Computer-assisted diagnosis of cardiac perfusion studies. *J Nucl Med Technol* 19 (4): 238-244, 1991.
10. Morton KA, Karwande SV, Davis RK, and Datz FL. Gastric emptying after gastric interposition for cancer of the esophagus. *Annals of Thoracic Surgery* 51: 759-763, 1991. PMID: 2025079.
11. Morton KA, Rose SC, Haakenstad AO, Datz FL, Handy JE and Scuderi AJ. Diagnostic use of angiotensin converting enzyme (ACE)-inhibited renal scintigraphy for the identification of selective renal artery stenosis in the presence of multiple renal arteries. *J Nucl Med* 31: 1847-1850, 1990. PMID: 2230999.
12. Patch GG, Morton KA, Arias JA and Datz FL. Naloxone reverses pattern of obstruction of the distal common bile duct induced by analgesic narcotics in hepatobiliary imaging. *J Nucl Med* 32 (6): 1271-1272, 1991. PMID: 1675267.
13. Datz FL and Morton KA. Radionuclide detection of occult infection: current strategies. *Cancer Investigation* 9: 689-696, 1991. PMID: 1747795.
14. Datz FL, Gullberg G, Gabor FV and Morton KA. SPECT myocardial perfusion imaging update. *Seminars in Ultrasound, CT and MR*, 12 (1):28-44, 1991. PMID: 1825916.
15. Datz FL, Christian PE, Hutson WR, Moore JG and Morton, KA. Physiological and pharmacological interventions in radionuclide imaging of the tubular gastrointestinal tract. *Seminars in Nuclear Medicine* XXI (2): 140-152, 1991. PMID: 1862349.
16. Morton KA, Jones BJ, Sohn M-H, Shaefer A, Phelps, R.Datz FL and Lynch RE: Uptake of cadmium is diminished in transfected cells enriched for metallothionein. *J Biol Chem* 267: 2880-2883, 1992. PMID: 1310676.
17. Datz FL, Gabor FV, Christain PE, Gullberg GT, Menzel, CE, and Morton KA. The use of computer-assisted diagnosis in cardiac perfusion nuclear medicine studies: a review. *J Digital Imaging* 5 (4): 209-222, 1992. PMID: 1862349.

18. Whiting JH, Morton KA, Datz FL, Patch GG, Miller FJ. Embolization of hepatic arterial malformations using radiolabelled and non-radiolabelled polyvinyl alcohol sponge in hereditary hemorrhagic telangiectasias. *J Nucl Med*, 33: 260-262, 1992. PMID: 1732452.
19. Arias JA, Morton KA, Albro JE, Patch GG, Valdivia S, Greenberg HE, Christian PE, Datz FL. Comparison of methods for identifying early methotrexate-induced hepatotoxicity in patients with rheumatoid arthritis. *J Nucl Med* 34: 1905-1909, 1993. PMID: 8229232.
20. Morton KA, Jones BJ, Shaefer A, Datz FL and Lynch RE: Enrichment for metallothionein in transfected NIH/3T3 cells does not impart resistance to cis-platinum. *J Pharmacol Exp Therapeut* 267: 697-702, 1993. PMID: 8246143.
21. Datz FL, Gabor FV, Christian PE, Gullberg GT, Menzel CE, and Morton KA. The use of computer-assisted diagnosis in cardiac perfusion nuclear medicine studies: A review (Part 2). *J Digital Imaging* 6: 1-15, 1993. PMID: 8439577.
22. Sohn M-H, Jones BJ, Whiting JH, Jr, Datz FL, Lynch RE and Morton KA. Distribution of gallium-67 in normal and hypotransferrinemic tumor-bearing mice. *J Nucl Med* 34: 2135-2143, 1993. PMID: 8254401.
23. Scuderi AJ, Datz FL, Valdivia S, Morton KA. Enthesopathy of patellar tendon insertion associated with isotretinoin therapy. *J Nucl Med* 34: 455-458, 1993. PMID: 8441038.
24. Datz FL, Rosenberg C, Gabor FV, Christain PE, Gullberg GT, Ahluwalia, R, and Morton KA. Computer-assisted diagnosis of cardiac nuclear medicine studies: A Review (Part 3). *J Digital Imaging* 6 (2): 67-80, 1993. PMID: 8334175.
25. Datz FL, and Morton KA. New radiopharmaceuticals for detecting infection. *Invest Radiol*, 28: 356-365, 1993. PMID: 8478177.
26. Whiting JA, Datz FL, Morton KA. Cerebrovascular accident associated with dipyridamole thallium-201 imaging. *J Nucl Med* 34: 128-130, 1993. PMID: 8418253.
27. Ahluwalia R, Morton KA, Whiting JH, Jr., Menzel-Anderson C, and Datz FL. Scintigraphic appearance of the bone during external beam irradiation. *Clin Nucl Med*, 19: 385-387, 1994. PMID: 8039308.
28. Datz FL, Christian PE, Rosenberg C, Gabor FV, Banish MR, Clark RL, Bruner TA, Gullberg GT, and Morton KA. The use of artificial intelligence to interpret cardiac and pulmonary nuclear medicine images. *Nuclear Medicine Annual 1994* (ed. Leonard M. Freeman), pp. 141-180.
29. Ahluwalia R, Datz FL, Morton KA, and Anderson C. Bilateral fatigue fractures of the radial shaft in gymnasts. *Clin Nucl Med* 19 (8): 665-667, 1994. PMID: 7955740.
30. Datz FL, Anderson CE, Ahluwalia R, Whiting JH, Gabor FV, Morton KA, Christian PE, Crebs K, Neptune M and Rauh DA. The efficacy of Indium-111-polyclonal IgG for the detection of Infection and Inflammation. *J Nucl Med*. 1994 Jan;35(1):74-83. PMID: 8271064.
31. Datz FL, Castrovovo FP, Christian PE, Anderson CE, Crebs K, Morton KA and Rauh DA. Biodistribution and dosimetry of indium-111 polyclonal IgG in normal subjects. *J. Nucl Med*. 36 (12): 2372-2379, 1995. PMID: 8523134.

32. Taylor A Jr, Nally J, Aurell M, Blaufox D, Dondi M, Dubovsky E, Fine E, Fommei E, Geyskes G, Granerus G, Kahn D, Morton K, Oei H-Y, Russell C, Sfakianakis G and Fletcher J. Consensus report on ACE inhibitor renography for the detection of renovascular hypertension. *J Nucl Med* 37: 1876-1882, 1996. PMID: 8917196.
33. Morton KA, Pisani DE, Whiting JH, Jr., Cheung AK, Arias JM, and Valdivia S. Determination of Glomerular Filtration Rate using Tc-99m DTPA in Patients with Differing Degrees of Renal Function. *J Nucl Med Technol* 25: 110-114, 1997. PMID: 9239614.
34. Taylor A, Jr, Manatunga A, Morton K, et al. Multicenter trial validation of a camera-based method to measure Tc-99m Mercaptoacetyltriglycine, or Tc-99m MAG₃, clearance. *Radiology* 204: 47-54, 1997. PMID: 9205222.
35. Luttrupp CA, Jackson JA, Jones BJ, Sohn, M-H, Lynch RE and Morton KA. Uptake of gallium-67 in transfected cells and tumors absent or enriched in the transferrin receptor. *J Nucl Med*, *J Nucl Med* 39: 1405-1411, 1998. PMID: 9708518.
36. Taylor AT Jr, Fletcher JW, Nally JV Jr, Blaufox MD, Dubovsky EV, Fine EJ, Kahn D, Morton KA, Russell CD, Sfakianakis GN, Aurell M, Dondi M, Fommei E, Geyskes G, Granerus G, Oei HY. Procedure guideline for diagnosis of renovascular hypertension. *J Nucl Med* 39: 1297-1302, 1998. PMID: 9669414.
37. Luttrupp CA, Vu C, and Morton KA. Photo-degraded nifedipine promotes the transferrin-independent uptake of Ga-67 in cultured cells. *J Nucl Med*, 40:159-165, 1999. PMID: 9935072.
38. Morton KA. Extra-Skeletal Uptake of Bone Agents. *J Nucl Med Technol* 27:51-53, 1999, PMID: 10322578.
39. Christensen C, Glowniak JV, and Morton KA. The effect of gadolinium contrast medium on the uptake of radioiodine by the thyroid. *J Nucl Med Technol*, 28:41-44, 2000. PMID: 10763780.
40. Morton KA, Luttrupp CA, Rouillet J-B. Enhancement of the transferrin-independent uptake of gallium by tumors. *Metal Ions in Biology and Medicine*, 6: 567-569, 2000.
41. Morton KA, Jarboe J, and Burke E. Gallium-67 imaging in lymphoma: the tricks of the trade. *J Nucl Med Technol* 28: 221-232, 2000. PMID: 11142323.
42. Alison B. Gruen AB, Zhou J, Morton KA, and Milstone LM. Photodegraded nifedipine stimulates uptake and retention of iron in human epidermal keratinocytes. *J Inv Dermatol*, 116: 774-777, 2001. PMID: 11348469.
43. Clark PB, Case D, Watson NE Jr, Perrier ND, Morton KA. Enhanced scintigraphic protocol required for optimal preoperative localization before targeted minimally invasive parathyroidectomy. *Clin Nucl Med*. 2003 Dec;28(12):955-60. PMID:14663315.
44. Clark PB, Case D, Watson NE, Morton KA, Perrier ND. Experienced scintigraphers contribute to success of minimally invasive parathyroidectomy by skilled endocrine surgeons. *Am Surg*. 2003 Jun;69(6):478-83; discussion 483-4. PMID: 12852504.

45. Levine EA, Freimanis RI, Perrier ND, Morton K, Lesko NM, Bergman S, Geisinger KR, Williams RC, Sharpe C, Zavarzin V, Weinberg IN, Stepanov PY, Beylin D, Lauckner K, Doss M, Lovelace J, Adler LP. Positron emission mammography: initial clinical results. *Ann Surg Oncol*. 2003; Jan-Feb 10(1):86-91. PMID:12513966.
46. Clark PB, Gage HD, Brown-Proctor C, Buchheimer N, Calles-Escandon J, Mach RH, Morton KA. Neurofunctional imaging of the pancreas utilizing the cholinergic PET radioligand [18F]4-fluorobenzyltrozamicol. *Eur J Nucl Med Mol Imaging*. 2004 Feb;31(2):258-60. PMID: 1512970
47. Clark P, Wooldridge T, Kleinpeter K, Perrier N, Lovato J, Morton K. Providing optimal preoperative localization for recurrent parathyroid carcinoma: a combined parathyroid scintigraphy and computed tomography approach. *Clin Nucl Med*. 2004 Nov;29(11):681-4. PMID: 15483477.
48. Fahey FH, Gage HD, Buchheimer N, Smith HC, Harkness BA, Williams RC, Bounds MC, Mercier J, Robbins ME, Payne RM, Morton KA, Mach RH. Evaluation of the quantitative capability of a high-resolution positron emission tomography scanner for small animal imaging. *J Comput Assist Tomogr*. 2004 Nov-Dec;28(6):842-8. PMID: 15538162.
49. Clark PB, Perrier ND, Morton KA. Detection of an intrathyroid parathyroid adenoma using single-photon emission CT 99mTc sestamibi scintigraphy and CT. *AJR Am J Roentgenol*. 2005 Mar;184(3 Suppl):S16-8. PMID: 15728008.
50. Kraas J, Clark PB, Perrier ND, Morton KA. The scintigraphic appearance of subcapsular parathyroid adenomas. *Clin Nucl Med*. 2005 Apr;30(4):213-7. PMID: 15764873.
51. Christensen CR, Morton KA. Practical PET in Oncology. *Contemporary Diagnostic Radiology*, 2005, April 15; 28 (8): 1-8.
52. Barker DW, Zagoria RJ, Morton KA, Kavanagh PV, Shen P. Evaluation of liver metastases after radiofrequency ablation: Utility of 18F FDG PET and PET/CT. *AJR Am J Roentgenology*, 2005, 184:1096–1102
53. Stitzel JD, Gayzik FS, Hoth JJ, Mercier J, Gage HD, Morton KA, Duma SM, Payne RM. Development of a finite element-based injury metric for pulmonary contusion part I: model development and validation. *Stapp Car Crash J*. 2005 Nov;49:271-89. PubMed PMID: 17096278.
54. Christensen CR, Clark PB, Morton KA. Reversal of Hypermetabolic Brown Adipose Tissue in F18 FDG PET Imaging. *Clin Nucl Med*. 2006 Apr;31(4):193-6. PMID: 16550009.
55. Stubbs E, Kraas J, Morton KA, Clark PB. Brain abnormalities detected on whole-body 18F-FDG PET in cancer patients: spectrum of findings. *AJR Am J Roentgenol*. 2007 Mar;188(3):866-73. Review. PMID: 17312080.
56. Rodrigues RS, Miller PR, Bozza FA, Marchiori E, Zimmerman GA, Hoffman JM, Morton KA. FDG-PET in Patients at Risk for Acute Respiratory Distress Syndrome. A Preliminary Report. *Intensive Care Med*. 2008 Dec;34(12):2273-8. PMID: 18682917.

57. Willick SE, Kendall RW, Roberts ST, Morton K. An emerging imaging technology to assist in the localization of axial spine pain. *Phys Med Rehabil* 2009 Jan;1(1):89-92. PMID: 19627880.
58. Clark PB, Plaza MJ, Kraas J, Burbank N, Elster AW, Garg P, Garg S, Gage HD, Calles-Escandon J, Wagner JD, Morton K. Dual Radiotracer Analysis of Cholinergic Neuronal Changes in Prediabetic Mouse Pancreas. *Diabetes Technol Ther*. 2009, 11(2): 107-111. PMID: 19848577
59. Rodrigues RS, Bozza FA, Christian PE, Hoffman JM, Butterfield RI, Christensen CR, Heilbrun M, Wiggins RH 3rd, Hunt JP, Bentz BG, Hitchcock YJ, Morton KA. Comparison of Whole-Body PET/CT, Dedicated High-Resolution Head and Neck PET/CT, and Contrast-Enhanced CT in Preoperative Staging of Clinically M0 Squamous Cell Carcinoma of the Head and Neck. *J Nucl Med*. 2009 Aug;50(8):1205-1213. PMID: 19617339.
60. Clark PB, Kavanagh K, Gage HD, Garg P, Garg S, Calles-Escandon J, Wagner JD, Morton K. Enhanced cholinergic response in pancreata of nonhuman primates with impaired glucose tolerance shown on [18F]fluorobenzyltrozamicol positron emission tomography. *Diabetes Technol Ther*. 2009 Jul;11(7):451-5. PMID: 19580359
61. Wang L-M, Becker JS, Wu Q, Oliveira MF, Bozza FA, Shwager AL, Hoffman JM, Morton KA. Bioimaging of copper alterations in the aging mouse brain by autoradiography, laser ablation inductively coupled plasma mass spectrometry and immunohistochemistry. *Metallomics* 2010, 2: 348-353. PMID: 21072380
62. Becker JS, Matusch A, Palm C, Salber D, Morton KA, Becker JS. Bioimaging of metals in brain tissue by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) and metallomics. *Metallomics*. 2010 Feb;2(2):104-11. PMID: 21069140.
63. Rondina MT, Wanner N, Pendleton RC, Kraiss LW, Vinik R, Zimmerman GA, Heilbrun M, Hoffman JM, Morton KA. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. *Thromb Res*. 2012 Jan;129(1):22-7. Epub 2011 Jul 29. PubMed PMID: 21802118. PMID: 21802118.
64. Chen LL, Chen X, Choi H, Sang H, Chen LC, Zhang H, Gouw L, Andtbacka RH, Chan BK, Rodesch CK, Jimenez A, Cano P, Jones KA, Oyedeji CO, Martins T, Hill HR, Schumacher J, Willmore C, Scaife CL, Ward JH, Morton K, Randall LR, Lazar AJ, Patel S, Trent JC, Frazier ML, Lin P, Jensen P, Benjamin RS. Exploiting antitumor immunity to overcome relapse and improve remission duration. *Cancer Immunol Immunother*. 2012 Jul;61(7):1113-24 PMID: 22198309
65. Enslow MS, Zollinger LZ, Morton KA, Kadrmas DJ, Butterfield RI, Christian PE, Boucher KM, Heilbrun ME, Jensen RL, Hoffman JM. Comparison of F-18 Fluorodeoxyglucose and F-18 Fluorothymidine Positron Emission Tomography in Differentiating Radiation Necrosis from Recurrent Glioma. *Clin Nucl Med*. 2012 Sep;37(9):854-61. PMID: 22889774
66. Rondina MT, Lam UT, Pendleton RC, Kraiss LW, Wanner N, Zimmerman GA, Hoffman JM, Hanrahan C, Boucher K, Christian PE, Butterfield RI, Morton KA. 18F-FDG PET in the Evaluation of Acuity of Deep Vein Thrombosis. *Clin Nucl Med*. 2012 Dec;37(12):1139-45. PMID: 23154470.

67. Duff K, Foster NL, Dennett K, Hammers DB, Zollinger LV, Christian PE, Butterfield RI, Beardmore BE, Wang AY, Morton KA, Hoffman JM. Amyloid deposition and cognition in older adults: the effects of premorbid intellect. *Arch Clin Neuropsychol*. 2013 Nov;28(7):665-71. PMID: 23817438
68. Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. *Cancer Imaging*. 2015 Sep 3;15:15. PMID: 26335224
69. Edwards O, Yakish ED, Wang LM, Wu Q, Hoffman JM, Morton KA. Histamine Receptor 1 and 2 Antagonists Alter Biodistribution of Radioiodine. *J Nucl Med Technol*. 2015 Sep;43(3):214-9. PMID: 26111706.
70. Conlin CC, Zhang JL, Rousset F, Vachet C, Zhao Y, Morton KA, Carlston K, Gerig G, Lee VS. Performance of an efficient image-registration algorithm in processing MR renography data. *J Magn Reson Imaging*. 2016 Feb;43(2):391-397. PMID: 26174884
71. Zhang JL, Conlin CC, Carlston K, Xie L, Kim D, Morrell G, Morton K, Lee VS. Optimization of saturation-recovery dynamic contrast-enhanced MRI acquisition protocol: monte carlo simulation approach demonstrated with gadolinium MR renography. *NMR Biomed*. 2016 Jul;29(7):969-77. PMID: 27200499
72. Haddadin Z, Lee V, Conlin C, Zhang L, Carlston K, Morell G, Kim D, Hoffman J, Morton K. Comparison of performance of improved serum estimators of GFR to Tc-99m DTPA GFR methods in patients with hepatic cirrhosis *J Nucl Med Technol*. 2017 Mar;45(1):314-321. PMID: 28154020.
73. Rodrigues RS, Bozza FA, Hanrahan CJ, Wang LM, Wu Q, Hoffman JM, Zimmerman GA, Morton KA. (18)F-fluoro-2-deoxyglucose PET informs neutrophil accumulation and activation in lipopolysaccharide-induced acute lung injury. *Nucl Med Biol*. 2017 Jan 17;48:52-62. PMID: 28237630
74. Towner RA, Saunders D, Smith N, Towler W, Cruz M, Do S, Maher JE, Whitaker K, Lerner M, Morton KA. Assessing long-term neuroinflammatory responses to encephalopathy using MRI approaches in a rat endotoxemia model. *Geroscience*. 2018; 40:49-60. PMID: 29417380
75. Wang L-M, Wu Q, Kirk R, Salem AH, Horn KP, Hoffman JM, Yap J, Sonnen JA, Bozza FA, Rodrigues RS, Towner RA, Morton KA. Lipopolysaccharide endotoxemia induces amyloid- β and p-tau formation in the rat brain. *Am J Nucl Med Mol Imaging*. 2018 25;8(2):86-99. eCollection 2018. PubMed PMID: 29755842.
76. McCormick ZL, Conger A, Willick S, Beresford Z, Kendall R, Shah L, Hutchins T, Morton K. Does SPECT/CT imaging paired with clinical evaluation provide prognostic utility for short-term outcomes of targeted interventions for chronic axial spine pain? An exploratory study. *PMR+*. 2019 2(1):16-23.
77. Kirk RA, Kesner RP, Wang LM, Wu Q, Towner RA, Hoffman JM, Morton KA. Lipopolysaccharide exposure in a rat sepsis model results in hippocampal amyloid- β plaque and phosphorylated tau deposition and corresponding behavioral deficits. *Geroscience*.

2019; 41(4):467-481. doi: 10.1007/s11357-019-00089-9. Epub 2019 Aug 31. PMID: 31473912.

78. Towner RA, Saunders D, Smith N, Gulej R, McKenzie T, Lawrence B, Morton KA. Anti-inflammatory agent, OKN-007, reverses long-term neuroinflammatory responses in a rat encephalopathy model as assessed by multi-parametric MRI: implications for aging-associated neuroinflammation. *Geroscience*. 2019; 41(4):483-494. doi:10.1007/s11357-019-00094-y. Epub 2019 Sep 2. PMID: 31478121.

79. Damme NM, Fernandez DP, Wang LM, Wu Q, Kirk RA, Towner RA, McNally JS, Hoffman JM, Morton KA. Analysis of retention of gadolinium by brain, bone, and blood following linear gadolinium-based contrast agent administration in rats with experimental sepsis. *Magn Reson Med*. 2020 Jun;83(6):1930-1939. doi: 10.1002/mrm.28060. Epub 2019 Nov 1. PMID: 31677194.

80. Agarwal N, Nussenzeig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan BL. Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. *Clin Cancer Res*. 2020 May 1;26(9):2104-2110. doi: 10.1158/1078-0432.CCR-19-2591. Epub 2020 Jan 14. PMID: 31937614.

81. Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, O'Neil B, Lowrance W. ¹⁸F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. *Urol Oncol*. 2020 Jul;38(7):636.e1-636.e6. doi: 10.1016/j.urolonc.2020.03.021. Epub 2020 Apr 18. PMID: 32317221.

82. Bennett P, Morton KA. Nuclear Medicine Education Via Instagram: A Viable Method for Informal Lifelong Learning. *J Nucl Med Technol*. 2021 Mar 15;jnmt.120.261438. doi: 10.2967/jnmt.120.261438. Epub ahead of print. PMID: 33722921.

83. Towner RA, Gulej R, Zalles M, Saunders D, Smith N, Lerner M, Morton KA, Richardson A. Rapamycin restores brain vasculature, metabolism, and blood-brain barrier in an inflammaging model. *Geroscience*. 2021 Apr 13. doi: 10.1007/s11357-021-00363-9. Epub ahead of print. PMID: 33846885.

84. Salem AE, Zaki YH, El-Hussieny G, ElNoueam, KI, Shaaban AM, Koppula BR, Bustoros M, Salama M, Elsayes KM, Morton K, Covington M. An Overview of Selected Rare B-Cell Lymphoproliferative Disorders: Imaging, Histopathologic, and Clinical Features. *Cancers (Basel)*. 2021;13(22):5853. Published 2021 Nov 22. doi:10.3390/cancers13225853

85. Koppula BR, Morton KA, Al-Dulaimi R, Fine GC, Damme NM, Brown RKJ. SPECT/CT in the Evaluation of Suspected Skeletal Pathology. *Tomography*. 2021;7(4):581-605. Published 2021 Oct 11. doi:10.3390/tomography7040050

86. Maughan BL, Kessel A, McFarland TR, McFarland TR, SAyegh N, Nussenzeig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N. Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. *Oncologist*. 2021;26(12):1006-e2129. doi:10.1002/onco.13949

87. Binneboese A, Covington MF, Horn KP, Archibald ZG, Boucher KM, Morton KA, Hoffman JM. Correlation between FDG-PET uptake and survival in patients with primary brain tumors. *Am J Nucl Med Mol Imaging*. 2021 Jun 15;11(3):196-206. PMID: 34234998; PMCID: PMC8255218.
88. Fine GC, Zhu GG, Morton KA, Damme N, Koppula BR. Pineal Gland Metastasis From Gastric Carcinoid-A Rare Manifestation. *Clin Nucl Med*. 2022;47(1):56-58. doi:10.1097/RLU.00000000000003818
89. Pana TA, Savla J, Kepinski I, Fairbourn A, Afzal A, Mammen P, Drazner M, Subramaniam RM, Xing C, Morton KA, Drakos SG, Zaha VG, Sadek HA. Bidirectional Changes in Myocardial ¹⁸F-Fluorodeoxyglucose Uptake After Human Ventricular Unloading. *Circulation*. 2022 Jan 11;145(2):151-154. doi: 10.1161/CIRCULATIONAHA.121.056278.
90. Covington MF, Koppula BR, Fine GC, Salem AE, Wiggins RH, Hoffman JM, Morton KA. PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies. *Cancers (Basel)*. 2022 May 29;14(11):2689. doi: 10.3390/cancers14112689.
91. Koppula BR, Fine GC, Salem AE, Covington MF, Wiggins RH, Hoffman JM, Morton KA. PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies. *Cancers (Basel)*. 2022 May 27;14(11):2668. doi: 10.3390/cancers14112668.
92. Salem AE, Fine GC, Covington MF, Koppula BR, Wiggins RH, Hoffman JM, Morton KA. PET-CT in Clinical Adult Oncology-IV. Gynecologic and Genitourinary Malignancies. *Cancers (Basel)*. 2022 Jun 18;14(12):3000. doi: 10.3390/cancers14123000
93. Wiggins RH, Hoffman JM, Fine GC, Covington MF, Salem AE, Koppula BR, Morton KA. PET-CT in Clinical Adult Oncology-V. Head and Neck and Neuro Oncology. *Cancers (Basel)*. 2022 May 31;14(11):2726. doi: 10.3390/cancers14112726.
94. Fine GC, Covington MF, Koppula BR, Salem AE, Wiggins RH, Hoffman JM, Morton KA. PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors. *Cancers (Basel)*. 2022 Jun 8;14(12):2835. doi: 10.3390/cancers14122835.

NCBI MyBibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/kathryn.morton.1/bibliography/public/>

B. Chapters

1. Datz FL, Christian PE, Rosenberg C, Gabor FV, Banish M, Clark R, Bruner TA, Gullberg GT, and Morton KA (1994). The use of artificial intelligence to interpret cardiac and pulmonary nuclear medicine images. In: *Nuclear Medicine Annual*, Leonard Freeman (editor), Raven Press, Ltd., New York. 141-180
2. Morton KA (2007) Osteomyelitis, Temporal Bone. In *Diagnostic Imaging: Nuclear Medicine*, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT, 1-60
3. Morton KA (2007) Failed Back Surgery Syndrome. In *Diagnostic Imaging: Nuclear Medicine*, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 1-112
4. Morton KA, Caamaano E (2007). Insufficiency Fracture. In *Diagnostic Imaging: Nuclear Medicine*, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 1-118

5. Morton KA (2007) Fracture. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 1-124
6. Hanrahan C, Morton KA (2007). Skeletal Muscle Disorders. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 1-164
7. Morton KA (2007) Atherosclerosis. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 2-10
8. Morton KA (2007) Vascular Thrombosis. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 2-14
9. Morton KA (2007) Vascular Graft Infection. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 2-16
10. Morton KA (2007) Vascular Thrombosis. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Salt Lake City, UT. 2-14
11. Morton KA (2007) VQ Scan Overview. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 4-2
12. Morton KA (2007) Interstitial Lung Disease. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 4-20
13. Morton KA (2007) Granulomatous Disease. In Diagnostic Imaging: Nuclear Medicine, Morton KA (Editor), Amirsys, Salt Lake City, UT. 2-24
14. Morton KA (2007) Brain Imaging Overview. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 5-2
15. Morton KA (2007) Radiation Necrosis vs. Recurrent Tumor. In Diagnostic Imaging: Nuclear Medicine, Morton KA (Editor), Amirsys, Salt Lake City, UT. 5-44
16. Morton KA (2007) Ventricular Shunt Dysfunction. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Salt Lake City, UT. 5-54
17. Morton KA (2007) Normal Pressure Hydrocephalus. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Salt Lake City, UT. 5-58
18. Morton KA (2007) Heterotopic Gray Matter. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 5-64
19. Morton KA (2007) Brain Infection and Inflammation. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 5-70
20. Morton KA (2007) Thyroid Overview. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 7-2
21. Morton KA (2007) Medullary Thyroid Cancer. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 7-62

22. Morton KA (2007) GI Anatomy and Imaging Issues. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 8-2
23. Morton KA (2007) Hepatic Cirrhosis. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 8-46
24. Morton KA (2007) Hypersplenism. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 8-52
25. Morton KA (2007) Hepatoblastoma. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 8-60
26. Morton KA, Wasserman M (2007). Hepatocellular Carcinoma. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 8-64
27. Morton KA (2007). Adrenal Malignancy. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 8-74
28. Morton KA O'Malley JP (2007). Pheochromocytoma. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 8-80
29. Morton KA, O'Malley JP (2007). Islet Cell Tumors. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 8-140
30. Morton KA (2007). Intraabdominal Infection. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 8-144
31. Morton KA (2007). Renal Cortical Scar. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 9-2
32. Morton KA (2007). Renal Masses. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 9-20
33. Morton KA (2007). Obstructive Uropathy. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 9-40
34. Morton KA (2007). Testicular Cancer. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 9-56
35. Morton KA (2007). Phosphorus-32 Therapies. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 10-2
36. Morton KA (2007). Hepatic Arterial Y-90 Microspheres. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 10-4
37. Morton KA (2007). RBC Survival and Splenic Sequestration. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 10-12
38. Morton KA (2007). Red Cell Mass and Plasma Volume. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 10-14

39. Morton KA, Drosten R (2007). Lymphoma, Post-therapy Evaluation. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 11-10
40. Morton KA, Drosten (2007), R. Non-Hodgkin Lymphoma, Low Grade. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 11-16
41. Drosten R, Morton KA (2007). Non-Hodgkin Lymphoma, Staging. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 11-20
42. Morton KA (2007). Breast, Benign Disease. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 11-32
43. Morton KA (2007). Paraneoplastic Disorders. In Diagnostic Imaging: Nuclear Medicine, Morton KA and Clark PB (Editors), Amirsys, Salt Lake City, UT. 11-48

C. Books

1. Datz FL, Arias JM, Patch GG, and Morton KA. Nuclear Medicine: A Teaching File. Mosby Yearbook. Hanover, MD. 1992.
2. Diagnostic Imaging: Nuclear Medicine. Morton KA (lead author/editor) and Clark PB. Amirsys, Salt Lake City, 2007.
3. Committee on state of Molybdenum-99 production and utilization and progress toward eliminating use of highly enriched uranium. Adelstein SJ, Ruth TJ, Hu L-W, Hung JC, Jubin RT, Keeler EB, Kulcinski GL, Lewis JS, Morton KA, Peterson EJ, Raubenheimer T, Royal HD, Taw FL. National Academies of Sciences, Engineering, and Medicine. October, 2016. Molybdenum-99 for Medical Imaging. Washington, DC: The National Academies Press.

D. Abstracts

1. Morton K, Kushner J, and Burnham B. Biosynthesis of porphyrins and heme from 1,5-dioxoalate (DOVA) by intact hepatocytes. Clin. Res. 29: 34-A., 1981.
2. Morton K, Straka J, Burnham B, and Kushner J. In vivo conversion 4,5-dioxoalate (DOVA) to 5-aminolevulinic acid (ALA) and heme. Clin. Res. 30: 37-A., 1982.
3. Morton K, Alazraki N, Taylor A. "Diverging wall" sign of apical aneurysm on thallium 201 SPECT images. Clin. Nucl. Med. 10/95: 13. 1985.
4. Morton K, Alazraki N, Winge D, Lynch RE. Cadmium-109 uptake by tumors derived from Balb C/3T3 cell lines with varying degrees of the transformed phenotype. Federation Proceedings 45 (6): 1660 (#1047), 1986.
5. Fortner AA, Datz FL, Scuderi AJ, and Morton KA. Evaluation of human cardiac transplants with TI-201 SPECT imaging and radionuclide ventriculography. Radiology 169 (P): 173, 1988.
6. Fortner AA, Datz FL, Scuderi AJ and Morton KA. Gated blood pool analysis of human cardiac transplants. Clin Nucl Med 13 (9S): P13, 1988.

7. Fortner AA, Datz FL, Scuderi AJ and Morton, KA. Thallium-201 SPECT Imaging of human heart transplants. Clin Nucl Med; 13 (9S):12, 1988.
8. Datz FL, Christian PE, Morton KA, Greenberg HE and Moore JG. The effect of body position on the rate of gastric emptying. J Nucl Med; 29 (5);751 (#45), 1988.
9. Datz FL, Morton KA, Scuderi AJ. Utility of thallium-201 imaging in well-differentiated thyroid carcinoma. J Nucl Med 31 (5): 744 (#155), 1990.
10. Datz FL, Christian PE, Morton KA, Handy JE. The effect of exercise on the rate of gastric emptying. J Nucl Med 31 (5): 800 (#389), 1990.
11. Datz FL, Christian PE, Hutson WR, Moore JG, Morton KA. The effect of physical and psychological stress on gastric emptying (GE). J Nucl Med 31 (5): 800 (#390), 1990.
12. Morton KA, Datz FL and Karwande SV. The upright posture after meals is essential for gastric emptying in patients following gastric pull-up surgery for esophageal cancer. J Nucl Med 31 (5): 848 (#605), 1990.
13. Morton KA, Datz FL, Goates JJ, and Wooten WW. Comparison of methods for calculating glomerular filtration rate: Tc-99m DTPA scintigraphic analysis, protein-free and whole plasma clearance of Tc-99m DTPA and I-125 iothalamate clearance. J Nucl Med 31 (5): 914 (#892), 1990.
14. Arias JM, Morton KA, Datz FL, Patch G, Albro J. Comparison of methods for identifying mild-moderate hepatotoxicity in patients with rheumatoid arthritis treated with methotrexate. J Nucl Med 32 (5): 1048 (#588), 1991.
15. Morton KA, Rohlfing J, Datz FL, Patch G, Arias J. ACE-inhibited renal scintigraphy: Comparison of quantitative and qualitative factors in identifying patients with renovascular hypertension. J Nucl Med 32 (5): 1104 (#827), 1991.
16. Morton KA, Jones BJ, Lynch RE. Uptake of cadmium is diminished in transfected cells enriched for metallothionein. K.A. Morton , B.J. Jones, and R.E. Lynch. J of Cell Biol 115 (3, Vol II): 467a (#2717), 1991
17. Warnock SH, Collins DA, and Morton KA. Comparison of tumor uptake and nuclear medicine images of gallium-67, thallium-201, and [cobalt-57]-vitamin B-12 in sarcoma-bearing mice. Western Division AFCR Meeting, Carmel, CA, 1992.
18. Datz FL, Christian PE, Hutson WR, Moore JG, and Morton KA. Gastric emptying rate with variable oral erythromycin doing in diabetyc gastroparesis. J Nucl Med 33: 833 (#33), 1992.
19. Gabor FV, Datz FL, Christian PE, Gullberg GT, and Morton KA. The use of computer-assisted diagnosis for pulmonary embolism on ventilation-perfusion lung scanning. J Nucl Med 33: 1003 (#756), 1992.
20. Datz FL, Gullberg GT, Christian PE, Zeng GL, Hseih YL, Tung CH, Valdivia S, Ahluwalia R, Anderson CM, Morton KA. ROC comparison of simulaneous transfmision emission

tomography to routine SPECT for diagnosis of coronary artery disease on thallium imaging. J Nucl Med 34 (5): 71P(#281), 1993.

21. Datz FL, Anderson CM, Morton KA, Ahluwalia R, Whiting JH, Christian PE, Valdivia S, Crebs CK. Evaluation of the accuracy of In-111 polyclonal IgG for detecting infection. J Nucl Med 34 (5): 62P(#241), 1993.

22. Datz FL, Christian PE, Castronovo FP Jr, Valdivia S, Anderson CM, Morton KA, and Rauh DA. Human dosimetry studies of indium-111-labeled polyclonal IgG. J Nucl Med 34 (5) 157P (#769), 1993.

23. Banish M, Datz FL, Clark R, Christian PE, Lawson D, Gullberg GT, Valdivia S, Morton KA. Application of neural networks to ventilation-perfusion imaging for diagnosing pulmonary embolism. J Nucl Med 34 (5) 176P (#850), 1993.

24. Datz FL, Christian PE, Ahluwalia R, Gullberg GT, Zeng GL, Valdivia S, Morton K. Comparison of 3-D surface and transparency renderings to SPECT tomographic slice images for the detection of coronary artery disease. J Nucl Med 34 (5) 196P (#931), 1993.

25. Sohn M-H, Morton KA, and Datz FL. Transferrin-dependent and independent uptake of Fe-59 and Ga-67 in transformed and untransformed cells. J Nucl Med 34 (5) 220P (#1032), 1993.

26. Anderson CM, Datz FL, Morton KA, Ahluwalia R, Whiting JH, Holman JM. A study of the frequency of rejection mimicking urinoma on Tc-99m DTPA imaging of renal transplants. J Nucl Med 34 (5) 249 (#1155), 1993.

27. Taylor A, Reese L, Folks R, Jones M, Prato F, Kemp B, Kuhl D, Garcia E, Corrigan P, Williams H, Sorsdahl O, Morton K, and Halkar R. Preliminary results of a multicenter trial to determine the clearance of Tc-99m MAG3 by single sample and camera based techniques. J Nucl Med 34 (5) 251P (#1163), 1993.

28. Morton KA, Pisani DE, Whiting JH Jr., Arias JM, Valdivia S, and Datz FL. Determination of glomerular filtration rate with Tc-99m DTPA in patients with varying degrees of renal insufficiency. J Nucl Med 35 (5) 100P (#397), 1994.

29. Datz FL, Anderson CM, Whiting JH, Bruner TA, Valdivia S, Christian PE, Crebs CK, Morton KA, and Winship J. Comparison of a new technetium-99m FAB' fragment to label leukocyte for detection of infection. J Nucl Med 35 (5): 172P (#693), 1994.

30. Datz FL, Anderson CM, Christian PE, Bruner TA, Valdivia S, Whiting JH, Crebs CK, and Morton KA. Evaluation of accuracy of In-111 polyclonal IgG for detection of infection in patients with diminished renal function. J Nucl Med 35 (5): 175-176P (#706), 1994.

31. Morton KA, Wright KL and Stevens JS. Comparison of 2-point postural drainage with diuresis renography in the assessment hydronephrosis. J Nucl Med 37 (5): 46P (#174), 1996.

32. Morton KA and Willis GS. Effect of gadolinium and iodinated contrast agents on uptake of Ga-67 by mice, tumors and cells. J Nucl Med 39 (5): 11P (#35), 1998.

33. Christensen C, Glowniak JV, Brown P, Morton KA. The effect of gadolinium MRI contrast on uptake of radioiodine by the thyroid gland. J Nucl Med 39 (5): 259P (#1138), 1998.
34. Morton KA, Jackson JA, and Sohn M-H. Uptake of gallium-67 in transfected cells and tumors absent or enriched in the transferrin receptor. J Nucl Med 39 (5): 11P (#34), 1998.
35. Morton KA and Rouillet JB. Enhancement of tumor uptake of Ga-67 by photodegraded nifedipine. AACR Annual Meeting, 2002, #2086.
36. Clark PB, Watson Ne, Morton KA, Clark HP, Chiles C, Kavanagh PV, Brooks MA. F18-FDG uptake in lymphangitic carcinomatosis: three case reports. Exhibited at the Society of Thoracic Radiology meeting. San Francisco, California, March 24-28, 2002.
37. Clark PB, Watson NE, Morton KA, Clark HP, Chiles C, Kavanagh PV. Clinical spectrum of disease in diffuse, low-grade F18-FDG activity in the lungs of patients with known malignancy. Exhibited at the 88th Scientific Assembly and Annual Meeting of the Radiological Society of North America. Chicago, Illinois, December 1-6, 2002. Abstract: Radiology 2002; 225(P):198.
38. Kavanagh PV, Clark PB, Chiles C, Clark HP, Brooks MA, Morton KA. Non-neoplastic diseases in the chest demonstrating increased activity on FDG-PET scans. Exhibited at the 88th Scientific Assembly and Annual Meeting of the Radiological Society of North America. Chicago, Illinois, December 1-6, 2002. Abstract: Radiology 2002; 225(P):152.
39. Clark PB, Morton KA. Nuclear medicine case of the day. Education exhibit at the 88th Scientific Assembly and Annual Meeting of the Radiological Society of North America. Chicago, Illinois, December 1-6, 2002.
40. Shen P, Silberberg A, Clark P, Morton K, Coldwell D. Positron Emission Tomography to Assess Response of Hepatocellular Carcinoma to Yttrium-90 Theraspheres Treatment. J Gastrointest Surg. 2003; Feb;7(2):310-1.
41. Clark PB, Perrier ND, Watson NE, Morton KA. Minimally invasive parathyroidectomy requires revised scintigraphic protocol for optimal localization. Society of Nuclear Medicine 50th Annual Meeting. New Orleans, Louisiana, June 21-25, 2003. Abstract: J Nucl Med 2003; 44(S):
42. Clark PB, Gage HD, Buchheimer N, Smith H, Brown-Proctor C, Blair J, Mach R, Morton KA. Peripheral distribution of [18-F]-4-fluorobenzyltrozamicol: new opportunities for novel imaging. Society of Nuclear Medicine 50th Annual Meeting. New Orleans, Louisiana, June 21-25, 2003. Abstract: J Nucl Med 2003; 44(S):224P.
43. Clark PB, Levine EA, Freimanis RI, Weinberg IN, Adler LP, Beiline D, Williams RC, Lesko NM, Zawarzin V, Morton KA. Dedicated PET mammography: initial clinical results. Society of Nuclear Medicine 50th Annual Meeting. New Orleans, Louisiana, June 21-25, 2003. Abstract: J Nucl Med 2003; 44(S):286P.
44. Shen P, Silberberg A, Clark P, Morton K, Cirillo R, Coldwell D. Positron emission tomography to assess response of hepatocellular carcinoma to Yttrim-90 theraspheres treatment. J Gastrointest Surg 2003; 7:310-311.

45. Christensen CR, Clark PB, and Morton KA. Reversal of hypermetabolic brown adipose tissue on FDG PET. Presented at 51st Annual Meeting of the Society of Nuclear Medicine (2004).
46. Clark PB, Miller P, and Morton KA. FDG PET may predict development of ARDS in trauma patients. 51st Annual Meeting of the Society of Nuclear Medicine (2004).
47. Morton K, Christensen C, Clark P, Hoffman J. FDG PET identifies sources of infection in cancer patients with febrile neutropenia. 52nd Annual Meeting of the Society of Nuclear Medicine (2006). J. NUCL. Med. MEETING ABSTRACTS 47 (2007): 330P-b.
48. Hoffman JM, Christensen CR, Morton KA. Fusion of Tc-99m MAA SPECT to CT or MR in planning for Y-90 microsphere radioembolization. 53rd Annual Meeting of the Society of Nuclear Medicine (2007). J. NUCL. Med. MEETING ABSTRACTS 48 (2008): 141P-b.
49. Morton KA, Rodrigues RS, Bozza FA, Hoffman JA, Christian PE. Comparison of standard and high resolution contrast enhanced FDG PET/CT in head and neck cancer staging. World Molecular Imaging Congress (2008).
50. Morton KA, Wang L-M, Wu Q, Zimmerman GA, Rodrigues RS, Bozza FA, Hoffman JM and Christian PE. Uptake of glucose analogs by activated thrombotic cells. World Molecular Imaging Congress (2008).
51. Rodrigues RS, Morton KA. Molecular imaging of acute lung inflammation. RSNA Annual Meeting, 2009, Chicago, IL
52. Wang LM, Wu Q, Hoffman J, Christian P, J. Becker S, Morton K. Alterations in copper uptake, content and distribution in the brains of aging mice. Society of Nuclear Medicine Annual Meeting, 2010, Salt Lake City, UT. J. NUCL. Med. MEETING ABSTRACTS 51 (2010): 1759.
53. Hoffman J, Butterfield R, Christian P, Heilbrun M, Morton K. The utility of FDG PET-CT for the diagnosis of occult malignancy in patients with acute, unprovoked venous thromboembolism. Presented at Society of Nuclear Medicine 2011 Annual Meeting. J Nucl Med. May 1, 2011, Volume 52, Supplement 1: 1922. J. NUCL. Med. MEETING ABSTRACTS 52 (2011): 1922.
54. Hoffman J, Wang LM, Wu Q, Morton K. Uptake of 2-deoxyglucose analogs by thrombotically activated cells. Presented at Society of Nuclear Medicine 2011 Annual Meeting. J Nucl Med. May 1, 2011, Volume 52, Supplement 1: 327.
55. Enslow M, Morton K, Butterfield R, Christian P, Kadmas D, Heilbrun M, Jensen R, Hoffman J. Differentiation between recurrent primary brain tumor and radiation necrosis by FDG and FLT PET. Presented at Society of Nuclear Medicine 2011 Annual Meeting. J Nucl Med. May 1, 2011, Volume 52, Supplement 1: 1229.
56. Hoffman J, Butterfield R, Christian P, Christensen C, and Morton K. FDG-PET/CT in the evaluation of persistent febrile neutropenia in cancer patients. Presented at Society of Nuclear Medicine 2011 Annual Meeting. J Nucl Med. May 1, 2011, Volume 52, Supplement 1: 1373.

57. Zollinger L, Duff K, Butterfield R, Christian P, Thurfjell L, Foster N, Morton K, and Hoffman J. Evaluating the correlation of 18F-flutemetamol uptake with measures of memory function in non-demented seniors. Presented at Society of Nuclear Medicine 2012 Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 53 (2012): 1970.
58. Zollinger L, Morton K, Akerley W, Kadrmaz DJ, Christian P, Butterfield R, Boucher K, Hoffman JM. 18F-FDG and FLT PET for early prediction of response to targeted chemotherapy in advanced lung cancer. Presented at Society of Nuclear Medicine 2012 Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 53 (2012): 384.
59. Lauren Zollinger L, Lam U, Rondina M, Morton K, Butterfield R, Beardmore B, Christian P, and Hoffman J. 18F-FDG PET-CT in the evaluation of acute deep venous thrombosis. Presented at Society of Nuclear Medicine 2012 Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 53 (2012): 602.
60. Zollinger LV, Rodrigues RS, Bozza FA, Hoffman JM, Morton KA. Imaging acute endotoxin-induced lung injury in a rat model. Presented at Society of Nuclear Medicine 2012 Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 53 (2012): 603.
61. Zollinger L, Morton K, Rondina M, Lam U, Christian P, Butterfield R, Beardmore B, Hoffman JM. 18F-FDG PET-CT in evaluation of acute deep venous thrombosis. Presented at Society of Nuclear Medicine 2012 Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 53 (2012): 602.
62. Zollinger L, Morton K, Wang LM, Wu Q, and Hoffman J. Secondary neuroinflammation in a rat sepsis model. Presented at Society of Nuclear Medicine 2013. Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 54 (2013): 1765.
63. Zollinger L, Morton K, Agarwal N, Kadrmaz D, Christian P, Beardmore B, Butterfield R, and Hoffman J. 18F-FDG and FLT PET for early prediction of response to sunitinib in metastatic renal cell carcinoma. Presented at Society of Nuclear Medicine 2013 Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 54 (2013): 1605.
64. Horn K, Hoffman J, and Morton K. Age-related differences in secondary neuroinflammation and amyloid- β deposition in a rat sepsis model. Presented at Society of Nuclear Medicine 2013 Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 55: 1802.
65. Koppula BR, Dhatt H, and Morton K. Pictorial review of role of nuclear medicine imaging of paraneoplastic syndromes. Presented at Society of Nuclear Medicine 2013 Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 55: 1350.
66. Edwards O, Yakish E, Hoffman J, and Morton K. Histamine blockers alter biodistribution of radioiodine. Presented at Society of Nuclear Medicine 2013 Annual Meeting. J. NUCL. Med. MEETING ABSTRACTS 55: 1223.
67. Haddadin Z, Koppula B, Yap J, Hoffman J, Morton K. Does metabolic activity on FDG PET-CT predict clinical behavior of pancreatic adenocarcinoma (PAC). Presented at SNMMI 2015 Annual Meeting. Nucl Med Meeting abstracts 2015 56:1410
68. Morton K, Wang LM, Wu Q, Yap J, Hoffman J. Transcriptome analysis of sepsis-induced changes in the rat brain: Implications for amyloid- β deposition. Presented at SNMMI 2015 annual meeting. J Nucl Med abstracts 2015 56:1543

69. Haddadin Z, Lee V, Conlin C, Morrell G, Hoffman JM, Morton K. Comparison of improved serum estimators of GFR to Tc-99m DTPA plasma-clearance method in patients with hepatic cirrhosis. Presented at SNMMI 2016 Annual Meeting. J Nucl Med abstracts 2016 57:1242.
70. Oliver Edwards, Bhasker Koppula, John Hoffman, and Kathryn Morton. An analysis of national trends in common nuclear medicine procedures: 2006 through 2015. Presented at SNMMI 2017 Annual Meeting. J Nucl Med 2017 58:447
71. Salem AHE, Rodrigues RS, Hoffman JM, Towner, RA, Yap JT, Morton KA. Lipopolysaccharide Endotoxemia Results in Secondary Neuroinflammation and Deposition of Amyloid Beta and Phosphorylated Tau in the Rat. Presented at RSNA 2017.
72. Banerjee S, Morton KA, Christensen CR, Koppula BR. The Use of PET/CT for Diagnosing and Characterizing Perineural Metastases. Educational exhibit. RSNA 2017.
73. Towner R, Morton K. In Vivo Detection of Free Radicals in a Rat Model for LPS-Induced Encephalopathy using Molecular-Targeted MRI and Assessment of the Anti-Inflammatory Agent, OKN-007. Presented at World Molecular Imaging Congress 2018.
74. Damme N, Hoffman JM, Morton KA. Experimental sepsis in a rat model increases brain deposition of gadolinium from MRI contrast media. Presented at RSNA 2018
75. Towner R, Morton K. Brain Metabolite Detection in a Rat Model for LPS-Induced Encephalopathy using MRS and OKN-007 Therapy Assessment. Presented at World Molecular Imaging Congress 2019.
76. Damme,N, Towner,R, Hoffman,J, Morton,K, Analysis of Retention of Gadolinium by Brain, Bone and Blood Following Linear Gadolinium-Based Contrast Administration in Rats with Gram-Negative Endotoxin-Induced Experimental Sepsis. Presented at RSNA 2019